



European Parliament's Environment Committee Votes to Support New Proposal for the Regulation of New Genomic Techniques

January 25, 2024

- *The Environment Committee of the European Parliament votes in favour of the European Commission proposal to introduce a new regulation on plants obtained by certain new genomic techniques (NGTs) and their food and feed.*
- *The Committee's report indicates that NGTs have the ability to enhance agriculture by making crops more resilient and sustainable whilst providing unprecedented opportunities for European agriculture and food production.*
- *The proposed regulation identifies a 'Conventional-like' category of NGT products that would be regulated as conventional varieties, bringing EU policy closer to that of trading partners in UK, North and South America, India, Australia, and Japan*
- *Following the positive vote, the legislation will now move to a plenary session of the European Parliament on 5th to 8th of February for a vote on adoption.*

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- **Cibus, Inc. (Nasdaq: CBUS)**, a leading agricultural technology company that develops and licenses plant traits to seed companies, welcomes the vote of the Environment Committee of the European Parliament on 24th January in favour of new legislation for New Genomic Techniques (NGTs).

The legislation is part of a package of EU proposals to ensure resilient and sustainable use of the EU's natural resources. It describes a category of NGTs, classed as targeted mutagenesis and cisgenesis, producing modifications that could be obtained in nature or by conventional breeding. These are determined to be 'Conventional-like' and, once verified, would be regulated in the same way as conventional varieties.

Before the vote, an [open letter](#) from 35 Nobel Laureates and over 1400 scientists urged MEPs to support the legislation in order to foster innovation, enhance food security and boost climate resilience.

After the vote, MEP and rapporteur [Jessica Polfjård](#) said, "This proposal is critical for strengthening Europe's food safety in a sustainable manner. We finally have a chance to implement rules that embrace innovation and I look forward to concluding negotiations in the Parliament and with the Council as soon as possible."

Tony Moran, Senior Vice President of International Development and Government Affairs at Cibus, commented, "The committee vote is an important step in the EU process for legislation that improves alignment with EU trading partners. Timely adoption would also be a significant boost for innovators particularly in academia and small and mid-sized enterprises who are actively developing NGT products that could contribute to a sustainable EU agri-food system."

About the Cibus RTDS®-based High Throughput Breeding System

A key element of Cibus' technology breakthrough is its High Throughput Breeding Process (referred to as the Trait Machine™ System). The Trait Machine process is a crop specific application of Cibus' patented *Rapid Trait Development System*™ **RTDS**®). The proprietary technologies in **RTDS** integrate crop specific cell biology platforms with a series of gene editing technologies to enable a system of end-to-end crop specific precision breeding. It is the core technology platform for Cibus' Trait Machine: the first standardized end-to-end semi-automated crop specific gene editing system that directly edits a seed company's elite germplasm. Each Trait Machine process requires a crop specific cell biology platform that enables Cibus to edit a single cell from a customers' elite germplasm and grow that edited cell into a plant with the Cibus edits. Cibus has Trait Machine platforms developed for canola and rice and has already begun transferring their elite germplasm with Cibus edits back to customers.

The traits from Cibus' RTDS-based High Throughput Breeding System are indistinguishable from traits developed using conventional breeding or from nature. RTDS does not use any foreign DNA or transgenes. Under the European Commission current proposals, it is expected that products from Cibus' RTDS gene editing platform such as its pod shatter reduction trait and Sclerotinia resistance traits for Canola and Winter Oilseed Rape would be considered 'Conventional-like'.

Cibus believes that **RTDS** and the Trait Machine process represent the technological breakthrough in plant breeding that is the ultimate promise of plant gene editing: "High Throughput Gene Editing Systems operating as an extension of seed company breeding programs."

About Cibus

Cibus is a leader in Gene Edited Productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately \$300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in

exchange for royalties on seed sales. Cibus' focus is productivity traits for the major global crops such as canola, rice, soybean, and wheat. Cibus is a technology leader in high throughput gene editing technology that enables Cibus to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Using its Trait Machine Process, Cibus has developed a pipeline of five productivity traits including important traits for pod shatter reduction, Sclerotinia resistance and weed management. Its initial traits for pod shatter reduction and weed management are developed in collaborations with leading seed companies. Its other pipeline traits including Sclerotinia resistance are in advanced greenhouse and field trial stages.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus' operational and financial performance, Cibus' strategy, future operations, prospects and plans, including the anticipated regulatory environment are forward-looking statements. Forward-looking statements may be identified by words such as "anticipate," "believe," "intend," "expect," "plan," "scheduled," "could," "would" and "will," or the negative of these and similar expressions.

These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus' actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: changes in expected or existing competition; challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus' platform or trait product development efforts; Cibus' reliance on third parties in connection with its development activities; challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus' traits or that farmers and processors fail to work effectively with crops containing Cibus' traits; challenges that arise in respect of Cibus' production of high-quality plants and seeds cost effectively on a large scale; Cibus' need for additional funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; Cibus' ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus' technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus' ability to execute on its business plan; the Company's assessment of the period of time through which its financial resources will be adequate to support operations; and other important factors discussed in "Risk Factors of Cibus, Inc." filed as Exhibit 99.3 with Cibus' Current Report on Form 8-K, which was filed with the Securities and Exchange Commission (the "SEC") on June 1, 2023, as updated by the supplemental risk factors included in the Company's Current Reports on Form 8-K filed on October 18, 2023 and December 12, 2023, each as may be updated by any additional "Risk Factors" identified in Cibus' subsequent reports on Forms 10-Q and 8-K filed with the SEC. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Cibus' assessment of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement and involves such risks and uncertainties. Accordingly, the Company could use its available capital resources sooner than it currently expects.

In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.

CIBUS CONTACTS:

Investor Relations

Karen Troeber

ktroeber@cibus.com

858-450-2636

Jeff Sonnek – ICR

jeff.sonnek@icrinc.com

Media Relations

Colin Sanford

colin@bioscribe.com

203-918-4347

 Primary Logo

Source: Cibus US LLC